Partners — Past & Present
Autobahn Labs was created by Samsara BioCapital, a leader in life sciences investments, and Evotec, a global leader in drug discovery and development research, and KCK Ltd., a family investment fund investing in scientifically and technically challenging projects. The long-term investment philosophy combined with world-class drug discovery and development capabilities enable Autobahn Labs to accelerate the translation of scientific ideas to novel therapeutics. Dr. Larrick serves as Chairman of the Autobahn Scientific Advisory Board.
Velocity Pharmaceutical Development (VPD) was established in 2011 by Presidio Partners as an alternative model to develop attractive drug candidates that would otherwise be funded as part of a broader company financing or not be funded due to strategic reasons or resource limitations. The company’s founders, David Collier, Ed Schnipper, Jim Larrick, and Andy Perlman, recognized that many high potential drug candidates are underfunded or shelved due to the inherent inefficiencies in traditional drug development within small and large biotech and pharmaceutical companies. Their solution was to invest in drug candidates and not companies. This was the inspiration for the Velocity model that establishes a project focused company (PFC) to house drug candidates acquired from third parties. Over its ten year history, VPD founded a number of successful companies.
The mission of Corsalex is to identify, fund, and develop promising projects to treat C9orf72 ALS/FTD. Corsalex is a joint venture between KCK and Panorama Research, led by Dr. Larrick and Piero Mendez.
The Panorama Institute of Molecular Medicine is a leader in the development of new therapeutics based on fundamental scientific discoveries. As a non-profit biomedical research facility, we conduct basic and applied research that will lead to medical advances to treat a wide range of diseases from cancer to heart failure. The Panorama Institute of Molecular Medicine is partnered with Panorama Research Inc.
Baxalta Ventures, Mayo Clinic and Velocity Pharmaceutical Development formed Vitesse Biologics in June 2015 to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology.